1-3 of 3
Charles Holladay
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CPOP-R Versus CHOP-R As First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study

Free
Raoul Herbrecht, David MacDonald, MD, FRCPC, Florian Weissinger, MD, Martin Wilhelm, MD, Charles Holladay, MS, MD, Nam H. Dang, MD, PhD, Peter Holman, MD, Paul Cernohous, MS, Jack Singer, MD, Richard H. van der Jagt, MD, FRCPC
Journal: Blood
Blood (2011) 118 (21): 1605.
https://doi.org/10.1182/blood.V118.21.1605.1605
Published: 2011
Journal Articles

Phase 2 Study of Bortezomib Weekly or Twice Weekly Plus Rituximab in Patients with Follicular (FL) or Marginal Zone (MZL) Lymphoma: Final Results.

Free
Sven De Vos, MD, PhD, Shaker R. Dakhil, MD, FACP, Peter McLaughlin, Mansoor N. Saleh, MD, Robert Belt, MD, Christopher Flowers, MD, Charles Holladay, MD, Mark Knapp, MD, Anthony Boral, MD, PhD, Tracy Zhang, MS, Andre Goy, MD
Journal: Blood
Blood (2006) 108 (11): 694.
https://doi.org/10.1182/blood.V108.11.694.694
Published: 2006
Journal Articles

Bortezomib Plus Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma (NHL): A Phase 2 Study.

Free
Sven de Vos, Shaker Dakhil, Peter McLaughlin, Mansoor Saleh, Robert Belt, Christopher Flowers, Mark Knapp, Lowell Hart, Dipti Patel-Donnelly, Martha Glenn, Stephanie A. Gregory, Charles Holladay, Anthony Boral, Tracy Zhang, André Goy
Journal: Blood
Blood (2005) 106 (11): 17.
https://doi.org/10.1182/blood.V106.11.17.17
Published: 2005